BioCopy

The core of BioCopy's business is its proprietary end-to-end platform that combines artificial intelligence with automated robotics to accelerate the discovery and development of next-generation biotherapeutics, primarily for oncology. The business model is centered on leveraging this platform to become a key partner for the pharmaceutical industry, aiming to drastically reduce the R&D timeline for complex cancer drugs from approximately three years to just 12 months. This is achieved through a massively parallel screening process; for instance, where conventional methods might test 10-100 drug candidates, BioCopy's system can analyze up to 25,000 in parallel. This high-throughput capability is designed to lower development costs and increase the success rate of drug candidates reaching the market.

The company's service revolves around its integrated technology suite. This includes 'ValidaTe', a proprietary microarray-based technology for precision screening of interactions between cancer cell markers and potential drug candidates. In April 2024, BioCopy acquired Perspix Biotech GmbH, integrating its 'roPROTix' robotics and AI platform to create a fully automated lab. This combined system generates vast amounts of proprietary data, which feeds the company's AI models to predictively design and optimize multispecific biotherapeutics with enhanced efficacy and safety. BioCopy serves biopharmaceutical companies by characterizing and validating T-cell drug candidates and has entered collaborations with firms like Biocytogen and YUMAB to advance antibody development. While initially focused on bladder, ovarian, and lung cancers, BioCopy plans to expand into immunological and neurological diseases in the long term.